Show simple item record

dc.contributor.authorFernández-Bargiela, Noelia
dc.contributor.authorRotea-Salvo, Sandra
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorBalboa-Barreiro, Vanesa
dc.contributor.authorMartín-Herranz, Isabel
dc.contributor.authorCastro-Iglesias, Ángeles
dc.contributor.authorMena-De-Cea, Álvaro
dc.contributor.authorLópez-Calvo, Soledad
dc.contributor.authorVázquez-Rodríguez, Pilar
dc.contributor.authorMíguez-Rey, Enrique
dc.contributor.authorCid-Silva, Purificación
dc.date.accessioned2022-11-22T09:09:12Z
dc.date.available2022-11-22T09:09:12Z
dc.date.issued2020-10-13
dc.identifier.citationFernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Míguez-Rey E, Cid-Silva P. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022 Jul;29(4):207-211.es_ES
dc.identifier.issn2047-9956
dc.identifier.urihttp://hdl.handle.net/2183/32094
dc.descriptionObervational studyes_ES
dc.description.abstract[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse events (NPAEs) have been described. This study evaluated the safety and tolerability of DTG-based and EFV-based antiretroviral regimens in HIV-infected patients. Methods: A retrospective observational study was carried out in HIV-infected patients who started DTG- or EFV-based antiretroviral treatment from January 2008 to December 2018 at a reference hospital in north-western Spain. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed with SPSS software. Results: A total of 282 DTG- and 148 EFV-based therapies were initiated. During follow-up, statistically significant differences have been found between the rate of patients who discontinued DTG and EFV due to AEs (12.1% vs 35.8%, p<0.001) and the main AEs in both groups, NPAEs (8.2% vs 25.0%, p<0.001). Female gender (OR 2.610 (95% CI 1.327 to 5.133), p=0.005) was associated with discontinuations due to AEs. Patients with documented psychiatric disorders were at higher risk of discontinuation due to NPAEs (OR 4.782 (95% CI 1.190 to 19.220), p=0.027). The multivariate analysis showed a 61.2% risk reduction in benzodiazepine prescriptions in patients treated with DTG. In both groups, patients needed consultation and follow-up in the psychiatry unit (16.9% in the EFV group and 8.9% in the DTG group, p=0.021). Conclusions: We found a high rate of discontinuations due to AEs and NPAEs, prescription of benzodiazepines and a requirement for consultation in a psychiatric unit in both treatment groups, especially with EFV.es_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.relation.urihttp://dx.doi.org/10.1136/ejhpharm-2020-002374es_ES
dc.rightsThis article has been accepted for publication in European Journal of Hospital Pharmacy following peer review, and the Version of Record can be accessed online at BMJ web page.es_ES
dc.subjectHIV & AIDSes_ES
dc.subjectAdverse effectses_ES
dc.subjectClinical pharmacyes_ES
dc.subjectInfectious diseaseses_ES
dc.subjectSide effects of drugses_ES
dc.titleDiscontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleEuropean Journal of Hospital Pharmacyes_ES
UDC.volume29es_ES
UDC.issue4es_ES
UDC.startPage207es_ES
UDC.endPage211es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record